Objectives. Behç et's disease (BD), an auto-inflammatory vasculitis with oro-genital ulcerations, skin lesions and uveitis, is regarded as T cell mediated. A successful trial with rituximab suggests an additive role for B cells in the pathogenesis. Therefore, we studied B cell abnormalities in BD patients and the effect of TNF-blocking therapy.
Introduction
Behç et's disease (BD) is an auto-inflammatory vasculitis characterized by recurrent oro-genital ulcerations, skin lesions and uveitis. The pathogenesis is driven by an excessive T cell reaction triggered by hyperactive neutrophils [1] . TNF-a plays a central role, and increased levels of this cytokine are found in both serum and aqueous humour. Furthermore, patients have increased levels of soluble TNF receptors and TNF-producing cells in peripheral blood [2, 3] .
Evidence is growing that B cells might play a more eminent role in the pathogenesis of BD: B cells from BD patients display a disturbed response to antigen stimulation [4] . Furthermore, patients carry elevated levels of LA and anti-phospholipids [5, 6] , and elevated numbers of activated and memory B cells [7] . Finally, one pilot study reported significant improvement of BD uveitis following B cell depletion with rituximab, a humanized anti-CD20 mAb [8] .
Current treatment strategies for patients with BD involve immunosuppressive medication directed towards T cells and neutrophils [9, 10] . Colchicine inhibits neutrophil function and has been shown to be effective in mucocutaneous disease [9] . Furthermore, TNF blockers have been shown to be effective in ocular [11] and mucocutaneous BD [12] . However, up to 10% of these patients still become therapy refractory [11] .
In addition to blocking T cell responses, TNF blockers also affect T cell-mediated B cell responses [13] . Furthermore, in other T cell-driven chronic inflammatory diseases, such as RA, inflammatory bowel disease (IBD) and sarcoidosis, TNF blockers restore deviations in B cell populations. However, it remains unclear whether this is a direct effect of TNF-a levels or an indirect effect through modifications in the T cell compartment [1416] .
We here studied the involvement of B cells in the pathogenesis of BD and the effect of TNF blockers on B cells. Specifically, in-depth cellular and molecular analysis of B cells was performed on peripheral blood and inflamed tissues of patients with BD. Our work revealed local B cell infiltrates, as well as systemic signs of chronic B cell stimulation, which normalize upon treatment with TNF blockers.
Methods

Patients
Diagnostic work-up and detailed studies of blood and tissue biopsies of 36 patients with BD and healthy controls were performed following informed consent according to the Declaration of Helsinki and guidelines of the Medical Ethical Committee of the Erasmus MC. This study was approved by the Medical Ethical Committee of the Erasmus MC, reference number MEC-2011-172. Patients were diagnosed according to the International Study Group of BD Criteria [17] . Disease activity was measured using the BD Current Activity Form (BDCAF) [18] . [19] , using the following antibodies: IgMHorV450 (G20-127; BD), IgD-biotin (IA6-2), IgG-PE (G18-145), CD19-PE-Cy7 (SJ25C1), CD19-PerCP-Cy5.5 (SJ25C1), CD21-PE-Cy7 (B-ly4), CD27-PerCP-Cy5.5 (L128), CD27-APC (L128), CD38-APC-H7 (HB7) (all BD Biosciences, San Jose, CA, USA) and IgA-FITC (IS11-8E10; Miltenyi-Biotec GmbH, Bergisch Gladbach, Germany). Biotinylated antibodies were visualized with streptavidin Pacific Orange conjugate (Invitrogen, Carlsbad, CA, USA). Transitional, naïve mature, natural effector and IgD À memory B cells were purified from post-Ficoll mononuclear cells on FACSAria I as described before [20] . All fractions were obtained with a purity of >95% as determined by post-sort analysis.
Quantification of serum immunoglobulin levels
IgG, IgA and IgM serum levels were determined with an immunoturbidimetric method on a Hitachi Analyzer (Roche, Basel, Switzerland). IgA and IgG subclasses were determined using routine immunonephelometric assays in a diagnostic laboratory (Sanquin, Amsterdam, the Netherlands).
Molecular analysis of replication history and Ig gene rearrangements DNA was isolated from purified B cell subsets for quantification of the replication history with the kappa-deleting recombination excision circles (KREC) assay, for analysis of somatic hypermutations (SHMs) and the Igk restriction enzyme hot-spot mutation assay as described previously [20, 21] . IgA and IgG transcripts were amplified using familyspecific forward primers in the leader sequence of immunoglobulin heavy variable (IGHV) 3 and IGHV4/6, in combination with Ca or Cg consensus reverse primers [19, 22] . In addition, IGHV3/4-IGHJ rearrangements were amplified from DNA of sorted natural effector B cells. PCR products were cloned into PGEM-T easy vector (Promega, Madison, WI, USA) and sequenced on an ABIPRISM 3130XL (Applied Biosystems, Foster City, CA). Obtained sequences were analysed with the IGMTdatabase (http://www.imgt.org/), JoinSolver programme (http://joinsolver.niaid.nih.gov) and Bayesian estimation of Antigen-driven SELectIoN (BASELINe) [2325] . IgA and IgG receptor subclasses were determined using the immunoglobulin heavy locus (IGH) reference sequence (NG_001019).
Immunohistochemistry of tissue biopsies
After standard fixation, embedding and sectioning procedures tissue slides of skin, genital and intestinal ulcers www.rheumatology.oxfordjournals.org from six patients were stained with haematoxylin and eosin and antibodies recognizing CD4 (clone SP35), CD3 (2GV6), CD79a (SP18) (all Ventana, Tucson, AZ, USA), CD8 (C8/144 B), CD20 (L26), IgG (rabbit polyclonal) (all Dako Cytomation, Glostrup, Denmark), IgA (rabbit polyclonal; Cell Marque, Rocklin, CA, USA), CD138 (B-A38; IQ Products, Groningen, The Netherlands) and IgM (IgM88; Biogenex, Fremont, CA, USA).
Statistics
Numbers of circulating blood cells subsets, SHMs and replication histories of B cells from patients and controls were statistically analysed using the non-parametric MannWhitney test (SPSS version 18.0; SPSS Inc., Chicago, IL, USA). Distributions of IgA and IgG subclasses and targeting of specific nucleotides in IGHV regions of B cells from patients and controls were analysed with the chi-square test. P < 0.05 was considered statistically significant.
Results
Clinical and immunological evaluation of BD patients
Thirty-six patients (17 males) were included with a mean (S.D.) age of 44 (12) years, a disease duration of 10 years and mean disease activity of 2.7 years (Table 1) . Patients 128 were not treated with any immunosuppressives for 3 months prior to analyses, except for colchicine in 15 patients, dapsone and HCQ in patient no. 3 and SSZ in patient no. 17 (Supplementary Table S1 , available at Rheumatology Online). In addition, we included eight patients who had been on adalimumab for >6 weeks and responded well. Twenty-two age and sex matched healthy controls were included.
Total T cell numbers of five patients were below the normal range; this was found for NK cells in nine patients. This was not related to medication or infection. Finally, in 6 of 28 patients circulating CD19 + B cells were below the normal range. Nearly all patients had normal levels of serum immunoglobulins, with only three patients showing a reduction in IgG, IgA or IgM (Supplementary Table 2 , available at Rheumatology Online). Thus, the included patients did not show overt defects in blood lymphocytes or immunoglobulins.
Disease activity-related reduction of blood memory B cell numbers
For detailed analysis of B cell defects in BD patients, we analysed peripheral blood B cells in 28 subjects that did not receive high dose immunosuppressives. Using eightcolour flowcytometry, we defined two naïve, one anergic 
Disturbed antigen-dependent B cell maturation in BD patients
To study the nature of the altered B cell compartment in patients with BD, we performed molecular analysis of naïve and memory B cells. Using the KREC assay, it was found that transitional B cells did not show signs of proliferation and that naïve mature B cells of patients had undergone two cell division, similar to healthy controls ( Fig. 2A ). This limited proliferation had occurred in the absence of SHMs, as evidenced with the Igk restriction enzyme hot-spot mutation assay (Fig. 2B) .
Natural effector B cells of patients showed significantly less proliferation (P = 0.0133) than controls (6 vs 9 cycles). Still, the frequencies of mutated Vk320 alleles and mutations in rearranged IGHV regions in natural effector B cells of patients were slightly higher than in controls ( Fig. 2B and C) , thereby showing signs of antigen maturation. Targeting of these mutations to hotspot motifs for activation-induced cytidine deaminase, RGYW motifs or polymerase Z, WA/TW motifs, was normal, reflecting normally induced SHM processes (Supplementary Table 3 , available at Rheumatology Online).
IGHV regions of natural effector B cells in both patients and controls showed high replacement/silent mutation rations in complementarity determining regions (CDRs) (Supplementary Table 3 , available at Rheumatology Online), suggestive of antigen-driven selection. Despite increased replacement mutations are thought to be a sign of selection, the increased replacement/silent mutation ratios in CDRs vs framework regions (FRs) do not necessarily reflect selection processes. The codon usage in CDRs is known to differ from FRs in their nature to be more susceptible to replacement mutations [26, 27] . Therefore, we analysed the IGH sequences with the BASELINe programme that determines whether the mutation patterns differs from what can be expected from random targeting [25] . In contrast to FRs, the CDRs of natural effector B cells from controls carried more replacement mutations than expected based on random chance (Fig. 2D) Fig. 2A) . Although mutated Vk320 alleles were increased (Fig. 2B) , independent analysis of SHMs in IGHV regions of IgA and IgG transcripts revealed increased frequencies only in IgA and not in IgG transcripts (Fig. 2C) . Still, targeting for activation-induced cytidine deaminase or polymerase Z hotspot motifs and selection for replacement mutations in CDRs was normal for both isotypes (Supplementary Table 3 , available at Rheumatology Online; Fig. 2D ).
To study the nature of the high SHM levels in IgA, we determined the IgA subclass usage in all transcripts. BD patients showed significantly less usage of the downstream IgA2 subclass (Fig. 3A) . Still, this was not the cause of the high SHM frequencies, because both IgA1 and IgA2 showed significantly higher SHM levels than controls (Fig.  3B) . Neither IgG subclass usage nor SHM levels were different from controls ( Fig. 3A and C) . Thus, despite the reduced numbers of CD27 + memory B cells, molecular signs of IgG memory seemed normal, while IgA showed increased signs of antibody maturation in BD patients.
B cell infiltrates in tissue with ulcerative inflammation
To further investigate whether the blood B cell abnormalities were due to involvement in the disease process, we performed a histological analysis of ulcerations in BD.
Haematoxylin and eosin-stained tissue biopsies of genital and intestinal ulceration showed ulcerative inflammation dominated by lymphocytes, histiocytes, and eosinophilic and neutrophilic granulocytes (Fig. 4) Differences between controls and patient groups were statistically analysed by using the MannWhitney test: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. (C) Absolute numbers of B cell subsets in cells per microlitre, controls compared with patients divided by disease activity. Controls (n = 22) are shown by white bars, patients with low disease activity (03) by light grey bars (n = 17) and patients with a high disease activity (>3) by dark grey bars (n = 11). Differences between controls and patient groups were statistically analysed by using the MannWhitney test: *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
under treatment with adalimumab for >12 months, and had responded well, as represented by low BDCAF scores (Table 1) . Those eight patients had significantly more total B cells than untreated patients, mainly due to increased numbers of memory B cells. CD27 + IgD À memory B cells (IgM only, IgA and IgG) were even 23 times higher than in controls (Fig. 5A) . CD21 low B cells of adalimumab-treated patients were increased as compared with controls and untreated patients. This increase concerned cells expressing any of the three major isotypes (IgM, IgG, IgA; Fig. 5B ). The rise in memory B cells was associated with a rise in CD21 low B cells.
Thus, patients with BD showed local and systemic abnormalities in their B cell compartments and these are, at least in part, corrected by TNF blockers.
Discussion
We here report reduced numbers of blood memory B cells and infiltration of B cells in ulcerations in patients with active BD. Following clinically successful treatment with TNF blockers these B cell aberrations disappear, suggesting an important direct or indirect role for B cells in the inflammatory cascade in BD. Our observations parallel another T cell-driven chronic disease, sarcoidosis. Patients with sarcoidosis have B cell infiltrates in granulomatous tissues and reduced blood memory B cells [14] . Similar to sarcoidosis, it is likely that memory B cells are localized at the site of inflammation in patients with BD. This infiltration of B cells into inflamed tissue has also been described for RA [16] . Several cases with B cell infiltrates in inflamed tissue of BD patients have been described before and are suggestive of an active role of B cells in the inflammatory process: CD20 + B cells were found in a ruptured pulmonary artery aneurysm and in three cases of neuro-Behç et [28, 29] ; skin biopsies from BD patients contain upregulated mRNA expression of B cell activating factor, a cytokine belonging to the TNF family [30] ; and a recent study showed high oral uptake of (99m)Tc-labelled rituximab in a patient with active oral BD [31] . How these B cells are involved in the inflammatory cascade in BD remains to be [25] . Differences between controls and patient groups were statistically analysed by using the MannWhitney test: *P < 0.05; ***P < 0.001.
www.rheumatology.oxfordjournals.org determined, as besides being mediators of inflammation, they could also have a regulatory function through production of IL-10. Although the histological evidence in this study was limited to a selected number of cases, we consistently observed B cell infiltrates in all studied patients and in all different tissue samples. Furthermore, previous cases of B cell infiltrates in inflamed tissue of BD patients have been reported [28, 29, 31] . Together with our findings of systemic B cell defects, these strongly suggest a role for B cells in this chronic inflammatory disease. We observe a reduction in memory B cells in peripheral blood of patients with BD. Regarding natural effector B cells, this reduction can at least partially be explained by reduced proliferation. This proliferation deficit, as demonstrated by our KREC analysis, might be influenced by alterations in TLR functioning, which is pivotal for the development and survival of these B cells [32] . Indeed, BD patients have defects in TLR1/2 and -4 responses to cognate agonists [33] . Reduced numbers of natural effector B cells were previously found in a similar inflammatory condition affecting the intestinal tract, namely IBD [15, 34] . Natural effector B cells are, at least in part, related to splenic marginal zone B cells [35] , which are highly exposed to antigens and serve as frontline defence players producing innate-like antibodies [32] . Splenectomized patients lack natural effector B cells and in these patients localized infections more frequently develop into invasive disease, which is also observed in BD patients [36] . On top of reduced proliferation and total numbers, the remaining natural effector B cells also displayed impaired defective selection of SHM. These combined defects could be related to the clinical inflammatory symptoms of BD.
IgA-producing B cells are able to switch to IgA2 as an adaptive response to lipopolysaccharide-containing bacteria in order to protect the intestinal mucosa [37] . We found reduced class-switched memory B cells with additionally reduced IgA2 subclass usage. Since these cells showed normal proliferation and high SHM levels, it is likely that these are triggered, but in an unconventional fashion as opposed to controls. Thus, the memory B cells could be impaired in their function. Interestingly, SHM levels are tightly regulated in individuals and do not seem to be affected by high infectious pressure, such as experienced by villagers in Papua New Guinea [38] . As SHM levels are also increased in patients with sarcoidosis [14] , this appears to be typical for pathogenic inflammation. In contrast to IgA, IgG + memory seems The observed increase in CD38 dim CD21 low B cells concerns an anergic B cell population with a silent B cell receptor, which is also found in blood of patients with RA common variable immunodeficiency and SLE, and individuals infected with human immunodeficiency virus [39, 40] . Interestingly, the numbers of these cells were associated with disease activity, even in patients treated with adalimumab. Therefore, the CD38 dim CD21 low population might serve as a predictive factor for potential disease severity. The exact mechanism by which this population is formed and how it is involved in autoimmune processes have not yet been elucidated and warrant more research into these cells. Effective treatment with TNF blockers was accompanied by normalization of the normal numbers of circulating memory B cells. TNF blockers are effective in ocular [11] and mucocutaneous BD [12] , suggesting that interruption of the inflammatory process by inhibition of TNF-a restores the memory B cell compartment. Because transitional and naïve mature B cell numbers were not different between adalimumab-treated patients and untreated patients or controls, the rise in memory B cells was not likely to result from de novo generation, but rather from relocalization from previously inflamed tissue to the circulation. Relocalization of memory B cells to inflamed tissue, as well as normalization of blood cell numbers after treatment with TNF blockers, was previously observed in patients with RA and sarcoidosis [15, 16] . In AS, TNF blockers resulted in a rise in unswitched CD27 À B cells, together with a decrease in SHMs, suggestive of a diminished germinal centre reaction [13] . The normalization of both natural effector B cells and class switched B cells is in line with these observations. Still, it remains unclear whether the increase in natural effector B cells is the result of normalization from T cell-dependent responses in the germinal centre, or T cell-independent responses in the marginal zone, as this subset in blood is likely a mixture of both [19] . Our observations mark yet again the position of BD at the junction of auto-inflammatory and auto-immune diseases, with the possible involvement of B cells as an argument for an, at least partial, auto-immune nature.
In conclusion, through extensive cellular and molecular analysis, we demonstrate that deviations in the memory B cell compartment are associated with active disease in patients with BD, and that these normalize www.rheumatology.oxfordjournals.org after effective treatment with TNF blockers. We hypothesize that memory B cells are recruited from the circulation to the site of inflammation, resulting in the abnormalities observed in peripheral blood of patients with active BD. Importantly, we observed an inverse correlation between CD27 + IgA + B cell numbers and disease activity. Therefore, these cells could serve as a marker for disease activity at diagnosis and during follow-up of treatment. . Differences were statistically analysed by using the MannWhitney test: *P < 0.05; **P < 0.01; ***P < 0.001.
